Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy

References

• Plotz PH, Rider LG, Targoff IN, et al. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122(9):715–724. doi:10.7326/0003-4819-122-9-199505010-00010
   PubMed Web of Science ®Google Scholar
• Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin. 2014;32(3):595–628, vii. doi:10.1016/j.ncl.2014.04.007
   PubMed Web of Science ®Google Scholar
• Cox S, Limaye V, Hill C, et al. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis. 2010;13(2):117–124. doi:10.1111/j.1756-185X.2010.01472.x
   PubMed Web of Science ®Google Scholar
• Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8–23. doi:10.1111/joim.12451
   PubMed Web of Science ®Google Scholar
• Mammen AL, Allenbach Y, Stenzel W, et al. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord. 2020;30(1):70–92. doi:10.1016/j.nmd.2019.10.005
   PubMed Web of Science ®Google Scholar
• Mariampillai K, Granger B, Amelin D, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol. 2018;75(12):1528–1537. doi:10.1001/jamaneurol.2018.2598
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Mammen AL, Benveniste O, et al. Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28(1):87–99. doi:10.1016/j.nmd.2017.09.016
   PubMed Web of Science ®Google Scholar
• Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23(12):1044–1055. doi:10.1016/j.nmd.2013.08.007
   PubMed Web of Science ®Google Scholar
• De Bleecker JL, De Paepe B, Aronica E, et al. 205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25(3):268–272. doi:10.1016/j.nmd.2014.12.001
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48(6):607–612. doi:10.1093/rheumatology/kep078
   PubMed Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–99. doi:10.1016/j.rmed.2016.10.019
   PubMed Web of Science ®Google Scholar
• Watanabe E, Gono T, Kuwana M, et al. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis. Rheumatology. 2020;59(3):586–593. doi:10.1093/rheumatology/kez328
   PubMed Web of Science ®Google Scholar
• Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55. doi:10.1016/j.jaut.2019.04.001
   PubMed Web of Science ®Google Scholar
• Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, et al. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Res Ther. 2017;19(1):174. doi:10.1186/s13075-017-1383-0
   PubMedGoogle Scholar
• Scola RH, Werneck LC, Prevedello DM, et al. Diagnosis of dermatomyositis and polymyositis: a study of 102 cases. Arq Neuropsiquiatr. 2000;58(3B):789–799. doi:10.1590/s0004-282x2000000500001
   PubMed Web of Science ®Google Scholar
• Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;88(5):493–500. doi:10.1212/WNL.0000000000003568
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–678. doi:10.1002/ana.20464
   PubMed Web of Science ®Google Scholar
• Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010;67(1):53–63. doi:10.1002/ana.21805
   PubMed Web of Science ®Google Scholar
• Soponkanaporn S, Deakin CT, Schutz PW, et al. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathol Appl Neurobiol. 2019;45(4):410–420. doi:10.1111/nan.12498
   PubMed Web of Science ®Google Scholar
• Uruha A, Allenbach Y, Charuel JL. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol. 2019;45(5):513–522. doi:10.1111/nan.12519
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347. doi:10.1056/NEJM197502132920706
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407. doi:10.1056/NEJM197502202920807
   PubMed Web of Science ®Google Scholar
• Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3(2):e000507. doi:10.1136/rmdopen-2017-000507
   PubMed Web of Science ®Google Scholar
• Nuño-Nuño L, Joven BE, Carreira PE, et al. Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry. Int J Rheum Dis. 2019;22(8):1393–1401. doi:10.1111/1756-185X.13559
   PubMed Web of Science ®Google Scholar
• Bushby K, Finkel R, Birnkrant DJ, et al.; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93. doi:10.1016/S1474-4422(09)70271-6
   PubMed Web of Science ®Google Scholar
• Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology. 1998;50:764–767. doi:10.1212/WNL.50.3.764
   PubMed Web of Science ®Google Scholar
• Sakuta R, Murakami N, Jin Y, et al. Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis. J Child Neurol. 2005;20(7):597–602. doi:10.1177/08830738050200071201
   PubMed Web of Science ®Google Scholar
• Jain A, Sharma MC, Sarkar C, et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand. 2011;123(2):122–129. doi:10.1111/j.1600-0404.2010.01353.x
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol. 2016;186(3):691–700. doi:10.1016/j.ajpath.2015.11.010
   PubMed Web of Science ®Google Scholar
• Horai Y, Koga T, Fujikawa K, et al. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 2015;25(1):85–89. doi:10.3109/14397595.2014.900843
   PubMed Web of Science ®Google Scholar